Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement
Firm Will Pay As Much As $40m Per Year; No Admission Of Wrongdoing
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
